Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Pediatr Ophthalmol Strabismus ; 51 Online: e16-8, 2014 Mar 04.
Artigo em Inglês | MEDLINE | ID: mdl-25314309

RESUMO

Retinal dysplasia occurs in the setting of sporadic and syndromic holoprosencephaly, which often has associated ocular malformations. The pathology of this dysplasia, which includes rosettes, has been previously described. However, its funduscopic findings have not been well documented. The authors present the fundus images of a patient with severe holoprosencephaly with retinal dysplasia and bilateral optic nerve colobomas that resulted in death 2 weeks after birth.


Assuntos
Anormalidades Múltiplas , Coloboma/diagnóstico , Holoprosencefalia/diagnóstico , Nervo Óptico/anormalidades , Displasia Retiniana/diagnóstico , Evolução Fatal , Feminino , Idade Gestacional , Humanos , Recém-Nascido , Imageamento por Ressonância Magnética
2.
JAMA Ophthalmol ; 132(7): 832-7, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24789459

RESUMO

IMPORTANCE: Optisol-GS, the most common corneal storage medium in the United States, contains antibacterial but no antifungal supplementation. Most postkeratoplasty endophthalmitis and keratitis cases are now of a fungal origin. OBJECTIVE: To assess the efficacy and safety of voriconazole and amphotericin B in reducing Candida species contamination of Optisol-GS under normal storage conditions. DESIGN, SETTING, AND PARTICIPANTS: In vitro laboratory study using 15 pairs of research-grade donor corneas and 20-mL vials of Optisol-GS. INTERVENTIONS: Twenty vials of Optisol-GS were supplemented with either voriconazole at 1×, 10×, 25×, or 50× minimum inhibitory concentration (MIC) or amphotericin B at 0.25×, 0.5×, 1×, or 10× MIC. Known concentrations of Candida albicans and Candida glabrata were each added to a set of vials. Safety studies were performed by separating 15 pairs of donor corneas into unsupplemented Optisol-GS or Optisol-GS plus an antifungal. MAIN OUTCOMES AND MEASURES: Efficacy outcomes were viable fungal colony counts determined from samples taken on days 2, 7, and 14 immediately after removal from refrigeration and after warming to room temperature for 2 hours. Safety outcomes included percentage of intact epithelium and endothelial cell density on days 0, 7, and 14, as well as percentage of nonviable endothelial cells by vital dye staining on day 14. RESULTS: Growth of C albicans and C glabrata was observed in all voriconazole-supplemented vials. In contrast, there was no growth of either organism in amphotericin B-supplemented vials, except at 0.25× and 0.5× MIC on day 2, when viable counts of C glabrata were reduced by 99% and 96%, respectively. Compared with paired controls, with the exception of Optisol-GS plus amphotericin B at 10× MIC, donor corneas in supplemented Optisol-GS appeared to have no difference in endothelial cell density reduction, percentage of intact epithelium, or percentage of nonviable endothelial cells. CONCLUSIONS AND RELEVANCE: The addition of amphotericin B to Optisol-GS may significantly improve activity against contamination with Candida species, the primary cause of fungal infection after corneal transplantation. This study found significant endothelial toxic effects at the maximal concentration of amphotericin B.


Assuntos
Antifúngicos/farmacologia , Candidíase/prevenção & controle , Sulfatos de Condroitina/farmacologia , Córnea , Dextranos/farmacologia , Contaminação de Medicamentos/prevenção & controle , Gentamicinas/farmacologia , Soluções para Preservação de Órgãos/farmacologia , Anfotericina B/efeitos adversos , Anfotericina B/farmacologia , Antifúngicos/efeitos adversos , Candida albicans/efeitos dos fármacos , Candida glabrata/efeitos dos fármacos , Candidíase/microbiologia , Contagem de Células , Sulfatos de Condroitina/efeitos adversos , Contagem de Colônia Microbiana , Misturas Complexas/efeitos adversos , Misturas Complexas/farmacologia , Meios de Cultura Livres de Soro/efeitos adversos , Meios de Cultura Livres de Soro/farmacologia , Dextranos/efeitos adversos , Combinação de Medicamentos , Endotélio Corneano/efeitos dos fármacos , Endotélio Corneano/microbiologia , Endotélio Corneano/patologia , Gentamicinas/efeitos adversos , Humanos , Testes de Sensibilidade Microbiana , Preservação de Órgãos , Soluções para Preservação de Órgãos/efeitos adversos , Pirimidinas/efeitos adversos , Pirimidinas/farmacologia , Doadores de Tecidos , Resultado do Tratamento , Triazóis/efeitos adversos , Triazóis/farmacologia , Voriconazol
3.
J AAPOS ; 17(1): 103-4, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23313048

RESUMO

A 3-year-old girl with a history of bilateral retinoblastoma presented with a new right lower periorbital mass that showed calcifications on ultrasound. She had previously undergone systemic and intra-arterial chemotherapy for retinoblastoma but had no evidence of active disease for at least 6 months previously. Her family and oncologists feared that this mass was an extraocular metastasis of her retinoblastoma. On excision, it was diagnosed as a pilomatrixoma, an uncommon benign neoplasm that originates from the matrix of the hair root. This is the first reported case of pilomatrixoma in a patient with retinoblastoma.


Assuntos
Doenças do Cabelo/complicações , Pilomatrixoma/complicações , Neoplasias da Retina/complicações , Retinoblastoma/induzido quimicamente , Neoplasias Cutâneas/complicações , Antineoplásicos Alquilantes/uso terapêutico , Pré-Escolar , Pálpebras , Feminino , Doenças do Cabelo/diagnóstico por imagem , Doenças do Cabelo/cirurgia , Humanos , Melfalan/uso terapêutico , Pilomatrixoma/diagnóstico por imagem , Pilomatrixoma/cirurgia , Neoplasias da Retina/tratamento farmacológico , Retinoblastoma/tratamento farmacológico , Neoplasias Cutâneas/diagnóstico por imagem , Neoplasias Cutâneas/cirurgia , Ultrassonografia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA